Navigation Links
Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program.
Date:5/25/2010

ALLENTOWN, Pa. and CAMPBELL, Calif., May 25 /PRNewswire/ -- HunterHeart offers physicians and patients sophisticated risk characterization and personalized therapy guidelines for cardiovascular disease.  HNL will be performing a battery of advanced tests, offering an accompanying nutrition program, and wellness coaching.  Gerry Weiss, MD, Hunter's Medical Director stated:  "With appropriate risk characterization and treatment, cardiovascular disease can be prevented for many patients and MI and stroke events can be significantly reduced."

"HNL's reputation for quality, service and innovation is exceptional.  Hunter is delighted to be working with HNL to reduce cardiovascular disease in PA and NJ," stated Chris Riedel, Hunter's CEO.  HNL's President and CEO, David G. Beckwith Ph.D., stated that, "The HunterHeart program will assist our physicians in delivering comprehensive cardiovascular health advice to their patients, and establishes HNL as a center of excellence for preventive cardiology."

About Health Network Laboratories

Based in Allentown, Pennsylvania, Health Network Laboratories (HNL) is a multi-regional medical laboratory with technologically advanced facilities in Pennsylvania and New Jersey.  HNL serves the need of the public and health care communities performing almost 6 million clinical and pathology tests each year.  HNL is consistently rated highly by physicians and clients in all areas of laboratory performance and customer satisfaction.

HNL offers a full complement of clinical laboratory and anatomic pathology services, including highly specialized esoteric testing to hospitals, physicians, long-term and assisted living facilities, businesses and government agencies.  For more information, visit http://www.healthnetworklabs.com/

About Hunter Labs, Inc.

Hunter Laboratories is the largest locally owned and operated clinical reference laboratory in northern California.  HunterHeart is one of Hunter's proprietary disease detection and management programs that are being rolled-out across the U.S.  Hunter's Incelldx mRNA test for cervical cancer detection is also being introduced across the U.S.  This test is the only accurate HPV method for women under 30, and has better specificity for predicting CIN2/CIN3 on biopsy.  For more information, visit http://www.hunterlabs.com/.


'/>"/>
SOURCE Hunter Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
5. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
6. Home Health Monitoring May Significantly Improve Blood Pressure Control, Kaiser Permanente Study Finds
7. Accuray Incorporated to Present at Citi Global Health Care Conference
8. Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Inverness Medical Innovations to Attend the Citi Global Health Care Conference on May 26, 2010
10. Medco to Present at the 2010 Citi Investment Research Global Health Care Conference
11. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):